Tools
Chile's immunization campaign, which has reached over 3 million people, is out-performing those of Mexico, Brazil, Argentina and Spain.
Chile began to administer COVID-19 vaccines on February 3. By this Tuesday, just 21 days later, over 3 million people had received at least one dose, which is equivalent to 16% of the country's 19 million inhabitants. This percentage does not only far surpass its largest neighbors, such as Argentina (1.65%), Brazil (3.43%) and Mexico (1.4%), but is also higher than the rates in countries like Spain (9.59%) and is quite close to that of the United States (19.44%). The number of available vaccines and the speed of the operation, with at least 1,300 centers nationwide, has made this South American country a regional and global example.
Click here to keep reading: https://elpais.com/sociedad/2021-02-24/como-hizo-chile-para-vacunar-a-mas-de-tres-millones-de-personas-en-21-dias.html
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about each cookie under each consent category below.
Cookies categorized as "Necessary" are stored on your browser, as they are essential for enabling the basic functionality of the website.
We also use third-party cookies that help us analyze how you use this website, save your preferences, and provide content and advertising that is relevant to you.
You can choose to enable or disable some or all of these cookies, although disabling some may affect your browsing experience.
Necessary cookies are crucial for the basic functions of the website, and the website will not work as intended without them. These cookies do not store any personally identifiable data. .
Necessary cookies are crucial for the basic functions of the website, and the website will not work as intended without them. These cookies do not store any personally identifiable data. .
We use cookies to improve your browsing experience, show you personalized ads or content, and analyze our traffic. By clicking "Accept All," you consent to our use of cookies.